Patient-Owned Health Data Model Reduces Clinical Trial Recruitment Redundancy - The Clinical Trial Vanguard

The same patient, identified and re-consented for the third or fourth time across separate studies, is not an edge case. It is how clinical research is currently structured, and the inefficiency is measurable: every redundant records request, re-registration, and repeat consent conversation adds cost to the sponsor and time to a patient already managing a demanding diagnosis. The case building around patient-owned health data argues that the architecture itself is the problem, not the execution.

The traditional model treats each protocol as a discrete relationship. A trial opens, participants are found, data flows inward, and the relationship ends. But sponsors rarely stop needing evidence from the same populations once a study closes. Observational work, real-world outcomes, label extensions, and post-market commitments all draw on the same patient groups, rebuilt from scratch each time. What the patient-owned model proposes instead is a single consented relationship that persists across those activities, turning what was an episodic research interaction into ongoing infrastructure.